Proj3:Role of cytochrome P450 (CYP)1A/1B1 enzymes in the potentiation of neonatal lung injury in newbron mice exposed prenatally to PHs, and increased risk of premature infants to chronic lung disease
Project Summary
Pregnant women, living in the vicinity of superfund sites, who may be exposed to polycyclic
aromatic hydrocarbons (PAHs) that emanate from these sites, are at a higher risk for preterm
delivery. Preterm delivery requires the neonate to be subjected to supplemental oxygen
(hyperoxia), and this in turn could lead to chronic lung disease/ bronchopulmonary dysplasia
(BPD). We hypothesize that prenatal PAH exposure will exacerbate the effects of postnatal
supplemental oxygen in preterm neonates. The mechanisms by which PAHs potentiate BPD in
infants are not well understood. The central hypothesis of this project is that prenatal
administration of PAHs [i.e. benzo[a]pyrene (BP), or a mixture of benzo(a)pyrene (BP),
benzo(b)fluoranthrene (BbF), and dibenz[a]anthracene (DBA)], which are which are defined as
class B2 carcinogens by USEPA, will differentially exacerbate lung injury and alveolar
simplification in neonatal mice following postnatal hyperoxia, and that this effect will be altered in
mice lacking the gene for cytochrome P450 (Cyp)1a1 or 1a2 genes by mechanisms entailing a
combination of genotoxic and epigenetic mechanisms. We will also test the hypothesis that the
infants exposed prenatally to PAHs have a greater risk of developing BPD than those exposed to
lesser or no PAHs, and that human pulmonary cells exposed to remediated PAHs will exhibit
lesser toxicity than parent PAHs. In order to test these hypotheses, we propose the following Specific
Aims: (1). Specific Aim 1. To test the hypothesis that prenatal exposure of wild type (WT) (C57BL/6J)
mice to the PAH BP or a mixture of PAHs (BP + BbF + DBA) will result in exacerbation of lung injury and
alveolar simplification following postnatal hyperoxia, and this effect will be altered in mice lacking the gene
for Cyp1a1, 1a2 or 1b1. 2. To determine the mechanisms by which prenatal PAHs will alter the
susceptibility of neonatal mice to hyperoxia. 3. To test the hypothesis that mothers exposed to
PAHs (that are present in superfund sites) are at a greater risk for preterm delivery, and that these
infants will show increased susceptibility to develop BPD than those with lesser or no exposure.
Accomplishments of these aims could lead to novel strategies for the prevention/treatment in
premature infants of BPD, which is probably potentiated by maternal PAHs that emanate from
Superfund sites.
Public Health Relevance Statement
Project Narrative
Pregnant women, living in the vicinity of superfund sites, who may be exposed to polycyclic
aromatic hydrocarbons (PAHs) that emanate from these sites, are at a higher risk for preterm
delivery. We hypothesize that prenatal PAH exposure will exacerbate the effects of postnatal
supplemental oxygen in preterm neonates. Accomplishments of the aims of this project should
be beneficial to stakeholders such as EPA and ASTDR, as we will be able to extrapolate the
doses we give in animals to humans who might be exposed to PAHs.
National Institute of Environmental Health Sciences
CFDA Code
DUNS Number
051113330
UEI
FXKMA43NTV21
Project Start Date
28-February-2020
Project End Date
31-January-2026
Budget Start Date
01-February-2024
Budget End Date
31-January-2025
Project Funding Information for 2024
Total Funding
$384,096
Direct Costs
$205,091
Indirect Costs
$179,005
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Environmental Health Sciences
$384,096
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P42ES027725-05 6892
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P42ES027725-05 6892
Patents
No Patents information available for 5P42ES027725-05 6892
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P42ES027725-05 6892
Clinical Studies
No Clinical Studies information available for 5P42ES027725-05 6892
News and More
Related News Releases
No news release information available for 5P42ES027725-05 6892
History
No Historical information available for 5P42ES027725-05 6892
Similar Projects
No Similar Projects information available for 5P42ES027725-05 6892